Expression of DEL-1 in alveolar epithelial cells prevents lipopolysaccharide-induced inflammation, oxidative stress, and eosinophil recruitment in acute lung injury

Li, Ruirui; Zeng, Jianqiong; Ren, Tao

doi:10.1016/j.intimp.2022.108961

Cited by 7 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 C) illustrated that LPS induces the stimulation of leukocytes, immune cell responses, antimicrobial reactions, neuroinflammation signaling, IFNG immune responses, neutrophil immune responses, and mammalian infections. These outcomes align with previous reports indicating that LPS triggers and activates immune responses in various leukocytes, including eosinophils 21 , neutrophils 22 , macrophages 23 , T cells 24 , B cells 25 , and mast cells 26 .…”

Section: Discussionsupporting

confidence: 92%

“…This interaction leads to the increased production and release of chemokines and the activation of related signaling pathways, including the IL-17 signaling pathway, TNF signaling pathway, and chemokine signaling pathway. Consequently, immune cells, including eosinophils 21 , neutrophils 22 , macrophages 23 , T cells 24 , B cells 25 , and mast cells 26 are recruited and migrate to the site of bacterial invasion. This orchestrated immune response aims to combat infections by inducing inflammatory immune responses and engulfing pathogens 14 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Insights from bioinformatics analysis reveal that lipopolysaccharide induces activation of chemokine-related signaling pathways in human nasal epithelial cells

Tan,

Gu,

Zhu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Lipopolysaccharide (LPS) is known to elicit a robust immune response. This study aimed to investigate the impact of LPS on the transcriptome of human nasal epithelial cells (HNEpC). HNEpC were cultured and stimulated with LPS (1 μg/mL) or an equivalent amount of normal culture medium. Subsequently, total RNA was extracted, purified, and sequenced using next-generation RNA sequencing technology. Differentially expressed genes (DEGs) were identified and subjected to functional enrichment analysis. A protein–protein interaction (PPI) network of DEGs was constructed, followed by Ingenuity Pathway Analysis (IPA) to identify molecular pathways influenced by LPS exposure on HNEpC. Validation of key genes was performed using quantitative real-time PCR (qRT-PCR). A total of 97 DEGs, comprising 48 up-regulated genes and 49 down-regulated genes, were identified. Results from functional enrichment analysis, PPI, and IPA indicated that DEGs were predominantly enriched in chemokine-related signaling pathways. Subsequent qRT-PCR validation demonstrated significant upregulation of key genes in these pathways in LPS-treated HNEpC compared to control cells. In conclusion, LPS intervention profoundly altered the transcriptome of HNEpC, potentially exacerbating inflammatory responses through the activation of chemokine-related signaling pathways.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Insights from bioinformatics analysis reveal that lipopolysaccharide induces activation of chemokine-related signaling pathways in human nasal epithelial cells

Tan,

Gu,

Zhu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Inhibition of neutrophils by DEL-1 also exerted protective effects in other diseases, which seems to contradict the study by Wei et al. ( 46 , 48 , 117 ). Multiple actions of DEL-1, such as anti- and proinflammatory resolution ( 39 ), coronary vasodilation ( 41 ), inhibition of MMP2 activity ( 41 ) and promotion of angiogenesis ( 118 , 119 ), may protect the heart from MI-induced injury.…”

Section: Del-1 In Cvdscontrasting

confidence: 62%

Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target

Zhao

Zheng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Cardiovascular and metabolic diseases (CVMDs) are a leading cause of death worldwide and impose a major socioeconomic burden on individuals and healthcare systems, underscoring the urgent need to develop new drug therapies. Developmental endothelial locus-1 (DEL-1) is a secreted multifunctional domain protein that can bind to integrins and play an important role in the occurrence and development of various diseases. Recently, DEL-1 has attracted increased interest for its pharmacological role in the treatment and/or management of CVMDs. In this review, we present the current knowledge on the predictive and therapeutic role of DEL-1 in a variety of CVMDs, such as atherosclerosis, hypertension, cardiac remodeling, ischemic heart disease, obesity, and insulin resistance. Collectively, DEL-1 is a promising biomarker and therapeutic target for CVMDs.

show abstract

“…In previous reports, inhibition of neutrophil recruitment improved cardiac dysfunction and cardiac remodeling after MI [114][115][116]. Inhibition of neutrophils by DEL-1 also exerted protective effects in other diseases, which seems to contradict the study by Wei et al [46,48,117]. Multiple actions of DEL-1 may protect the heart from MI injury, such as anti-and pro-inflammatory resolution [39], coronary vasodilation [41], inhibition of MMP2 activity [41] and promotion of angiogenesis [118,119].…”

Section: Ischemic Heart Diseasementioning

confidence: 92%

Developmental endothelial locus-1 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target

Zhao

Zheng

et al. 2022

Preprint

View full text Add to dashboard Cite

Cardiovascular and metabolic diseases (CVMDs) are a leading cause of death worldwide and imposes a huge socioeconomic burden on individuals and healthcare systems, underscoring the urgent need to develop new drug therapies. Developmental endothelial locus-1 (DEL-1) is a secreted multifunctional domain protein that can bind to integrins and play an important role in the occurrence and development of various diseases. Recently, DEL-1 has attracted great interest for its pharmacological role in the treatment and/or management of CVMDs. In this review, we present the current knowledge on the predictive and therapeutic role of DEL-1 in a variety of CVMDs, such as atherosclerosis, hypertension, cardiac remodeling, ischemic heart disease, obesity, and insulin resistance. Collectively, DEL-1 is a promising biomarker and therapeutic target for CVMDs.

show abstract

Expression of DEL-1 in alveolar epithelial cells prevents lipopolysaccharide-induced inflammation, oxidative stress, and eosinophil recruitment in acute lung injury

Cited by 7 publications

References 32 publications

Insights from bioinformatics analysis reveal that lipopolysaccharide induces activation of chemokine-related signaling pathways in human nasal epithelial cells

Insights from bioinformatics analysis reveal that lipopolysaccharide induces activation of chemokine-related signaling pathways in human nasal epithelial cells

Developmental endothelial locus-1 in cardiovascular and metabolic diseases: A promising biomarker and therapeutic target

Developmental endothelial locus-1 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target

Contact Info

Product

Resources

About